Pfizer's Talzenna Approved for Earlier Use in Prostate Cancer Following Phase 3 Trial Success on March 19, 2026 enzalutamide HRR gene mutation mCRPC Metastatic castration-resistant prostate cancer Pfizer Poly(ADP-ribose) Polymerase Inhibitors TALAPRO-2 talazoparib Talzenna Xtandi +
Thousands Could Benefit from New Take-at-Home Treatment for Advanced Prostate Cancer on January 23, 2026 enzalutamide Malignant neoplasm of prostate Nance-Horan syndrome Nitroglycerin/Sodium Citrate/Ethanol Solution talazoparib Talzenna +
Thousands Could Benefit from New Take-at-Home Treatment for Advanced Prostate Cancer on January 23, 2026 enzalutamide Malignant neoplasm of prostate Nance-Horan syndrome Nitroglycerin/Sodium Citrate/Ethanol Solution talazoparib Talzenna +
Pfizer, Astellas' Xtandi Combo Extends Survival in Early Prostate Cancer on July 12, 2025 Astellas BCR biochemical recurrence Combined Modality Therapy EMBARK enzalutamide leuprolide Malignant neoplasm of prostate nmHSPC non-metastatic Overall Survival Pfizer Xtandi +
FDA Advisory Committee Unanimously Votes Against Expanding Pfizer's Prostate Cancer Drug Combo on May 22, 2025 Advisory Committees enzalutamide expansion Inhibitor Labels (device) Malignant neoplasm of prostate mCRPC PARP1 gene Pfizer talazoparib Talzenna unanimous vote United States Food and Drug Administration +